MD Anderson Cancer Center, Department of Cancer Biology, The University of Texas
Ronald A. DePinho served until 2017 as president of MD Anderson Cancer Center, where he is now Professor in Cancer Biology and holds the Harry Graves Burkhart III Distinguished University Chair in Cancer Research. His basic and translational research program focuses on pathways and processes governing aging and age-related disorders, particularly cancer.
DePinho’s experimental approach is built upon the use of unbiased computational analyses of multi-dimensional datasets, genetically engineered mouse models, and human-mouse comparisons on the molecular, cellular and physiological levels. Through MD Anderson’s Institute for Applied Cancer Science, he strives to drive basic discoveries to therapeutic and diagnostic endpoints in a systematic action-oriented culture. His laboratory’s activities have focused on (i) defining the role of telomeres in governing cancer genome alterations, epithelial carcinogenesis, aging and degenerative disorder (both acquired and inherited), (ii) utilizing genetically engineered mouse models to study human cancers with an emphasis on comparative oncogenomics and proteomics to discover and ultimately validate new genes for enlistment into drug discovery, early detection or prognostic biomarkers; there is a focus on glioblastoma, pancreatic cancer, and prostate cancer, and (iii) elucidating pathways orchestrating aging and age-related disorders with the goal of therapeutically manipulating such pathways to attenuate the incidence of age-associated diseases such as cancer, cardiomyopathy and neurodegeneration. DePinho’s mission is to convert basic knowledge into clinical endpoints that will impact on patient outcomes in meaningful ways.
For his fundamental contributions to cancer and aging and to healthcare, DePinho has been recognized with numerous honors and awards. He is a member of the National Academy of Medicine and the National Academy of Science, and a fellow of the American Academy of Arts and Sciences, the American Association of the Advancement of Science and the American Association of Cancer Research.
Thursday, November 21
1:15 PM – 1:40 PM
Friday, November 22
1:30 PM – 1:40 PM